Its ‘Plug and Play’ modular bispecific antibody BiXAb platform enables BIOMUNEX to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties.

The BiXAb platform can also generate innovative bispecific antibodies in any other therapeutic areas, such as immune-mediated inflammatory diseases or infectious diseases or any other diseases in which therapeutic bispecific antibodies may provide benefit.

The most advanced candidate derived from BIOMUNEX’ platform, BMX-002, has demonstrated superior in vivo efficacy in pancreatic cancer, one of the most lethal cancers. Initial preclinical studies have proven its potential to become a breakthrough therapy in several solid tumors such as head & neck, gastric or colon cancers.

The BIOMUNEX 2nd lead candidate, BMX-101, an immunotherapeutic being developed for multiple myeloma and other hematological malignancies, leverages the power of immune checkpoint inhibition.

Research programs are ongoing with renowned academic teams, such as Institut de Recherche en Cancérologie de Montpellier; new programs are being established with additional academic teams.

The management team is represented by an experienced group of international managers and drug developers from the pharmaceutical and biotech industries, with extensive scientific expertise in oncology.